A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society

BACKGROUND: Capecitabine maintenance therapy is safe and efficacious for early-stage triple-negative breast cancer (TNBC) patients, but the cost-effectiveness of its long-term use has not been investigated. Here, we evaluated the cost-effectiveness of capecitabine maintenance therapy, compared with...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ji-Bin, Lin, Zhuo-Chen, Wong, Martin C. S., Wang, Harry H. X., Li, Mengmeng, Li, Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511760/
https://www.ncbi.nlm.nih.gov/pubmed/36156186
http://dx.doi.org/10.1186/s12916-022-02516-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511760/
https://www.ncbi.nlm.nih.gov/pubmed/36156186
http://dx.doi.org/10.1186/s12916-022-02516-9

Ejemplares similares